Brian Gorman

Brian Gorman


Recent articles

Thursday's Biggest Stock Stars

Yesterday's market is today's road map.

Kraft's Ever-Shifting Menu

Recent anemic results belie more promising future prospects.

Boeing's Continuing Climb

The company can consolidate its lead if it overcomes some challenges.

Merck's Special Interest

Merck is likely to succeed in getting states to mandate HPV vaccination.

Covance Stays Solid

Despite a run-up in the stock, Covance may be in for yet another solid year.

Southwest's Declining Edge?

Past advantages in fuel and labor expenses appear to be on the wane.

California Pizza Rising?

The company's EPS forecast is enticing, but is it enough to buy on?

Monsanto's Bigger Harvest?

High corn prices could allow Monsanto to raise seed prices and improve margins.

GM's Malibu Makeover

While it's no trailblazer, this new car model shows that the company is paying attention to the right things.

General Mills Rethinks Trix

The rise and fall of the company's low-sugar kids' cereals illustrates the pitfalls of responding hastily to media frenzies.

Novartis Cuts in Line at the Drugstore

Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure.

Defense Contractors Under Attack?

The stage could be set for budget shifts that will hurt some defense contractors and help others.

Monsanto Needs to Charm

The company has to confront concerns over genetically modified foods soon if it hopes to keep growing.

Yahoo!'s New Camera Crew

A new feature allows users the chance to make the news.

More Political Ire for Wal-Mart?

Christian conservatives could have had something to do with Wal-Mart's November weakness.

Hospira's Bold Move

The drug delivery outfit's stab at biosimilars is worth some attention, but investors shouldn't assume a major payoff.

Polo's Next Hurdle

The luxury goods purveyor looks poised to finish strong in fiscal 2007, but keeping up the pace will present a challenge.

Albany Molecular Plays the Odds

Will more investment in drug development hurt profitability?

Charles River Inches Forward

The company is not out of the woods yet, but some positive signs are emerging.

Novartis' China Gambit

Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore.